Shares of GeoVax Labs Inc. (GOVX) are up over 8% at $3.62 in premarket trading, driven by renewed concerns about the monkeypox outbreak.
GeoVax is a clinical-stage biotechnology company focused on developing human vaccines for many of the world's most threatening infectious diseases and therapies for solid tumor cancers using novel proprietary platforms. Preclinical and research programs for preventive vaccines against Mpox and Smallpox, dubbed GEO-MVA, are also underway.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com